Johnson & Johnson (NYSE:JNJ) Shares Sold by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 7.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 108,502 shares of the company's stock after selling 9,248 shares during the period. Stratos Wealth Partners LTD.'s holdings in Johnson & Johnson were worth $17,994,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson in the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $29,000. Conquis Financial LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $33,000. Bernard Wealth Management Corp. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $36,000. Finally, Highline Wealth Partners LLC raised its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on JNJ. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Morgan Stanley reissued an "underperform" rating on shares of Johnson & Johnson in a research note on Thursday. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Barclays dropped their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $171.00.

Johnson & Johnson Stock Performance

NYSE:JNJ traded down $0.82 during trading hours on Friday, hitting $156.87. 7,866,488 shares of the company were exchanged, compared to its average volume of 8,077,942. The stock has a market capitalization of $377.44 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The company's 50 day moving average price is $153.75 and its 200-day moving average price is $154.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.